INDEX OF SUBJECTS FOR VOLUME 31

Adherence
  EPEC adherence factor, 251
  of *S. milleri* group, 259
Aggregation
  S. milleri group by saliva, 259
Ampicillin, and *L. pneumophila*, 37
Anaerobes
  in broken mouth periodontitis, 275
  in sputum of cystic fibrosis patients, 271
Antibiotic resistance
  chloramphenicol, and *S. pneumoniae*, 133
  methicillin, and *S. aureus*, 4, 11, 57, 125
  4-quinolones, resistance mechanisms, 153
Antibiotics and other antimicrobial substances
  4-quinolones, and *E. coli*, 65
  responses of *L. pneumophila*, 37
  sensitivity of *S. aureus*, 57
Antibodies
  against *H. influenzae*, 163
  against *S. choleraesuis*, 225
  against *S. minnesota*, 85
  against *S. typhimurium*, 225
  see also Monoclonal antibodies
Antigens
  of enterotoxigenic *E. coli*, 185
  lipopolysaccharide, of *S. minnesota*, 85
  lipopolysaccharide, of *S. typhimurium*, 95
  outer membrane proteins of *H. influenzae*, 163
Antisera
  against *C. difficile* toxin B, 251
  against *H. ducreyi*, 219
  against *S. minnesota*, 85

Bacteraemia, *E. coli* in, 175
Bacteriophage *see* Phage typing
Bacteroides spp.
  in broken mouth periodontitis, 275
  in sputum of cystic fibrosis patients, 271
Biotyping, of *S. aureus*, 125
BOOKS RECEIVED
  DNA probes for infectious diseases (edited by F. C. Tenover), 152
  The biology of parasitism. A molecular and immunological approach (edited by P. T. Englund and A. Sher), 72
  Tumorigenic DNA viruses (edited by G. Klein), 72
Broken mouth periodontitis, 275

Cefotaxime, and *L. pneumophila*, 37
Cell-surface charge, 259
Cell wall synthesis, by *L. pneumophila*, 37
Cerebrospinal fluid (CSF)
  diagnosis of bacterial meningitis, 21
Chloramphenicol acetyltransferase, 133
Chloramphenicol resistance of *S. pneumoniae*, 133
Cholera toxin, and ileal loops, 27
Chromatography, gas, 21, 275
Chromosomal aberrations
  cytogenetic effects of viral vaccines, 11
Ciprofloxacin
  DNA degradation in *E. coli*, 65
  response of *L. pneumophila*, 37
Clostridium difficile
  detection of toxin B, 251
  hydrolytic enzyme activity, 169
Co-agglutination tests, *N. meningitidis*, 195
Co-aggregation
  S. milleri group and oral bacteria, 259
Concanavalin A, 191
Corynebacterium spp.
  pyrolysis-mass spectrometry, 137
Cystic fibrosis patients, 119, 271
Cytotoxic necrotising factor, 175
Cytotoxicity tests, *C. difficile* toxin B, 251
Cytotoxins
  Vero cytotoxin genes, 235

Diarrhoea
  enteropathogenic *E. coli*, 235
  mouse model for enterotoxigenic *E. coli*, 185
Dihydrofolate reductases, 1, 213
Disk-diffusion methods, 133
DNA
  degradation by 4-quinolones, 65
  gyrase enzyme, 153
  hybridisation, 9, 45, 207, 213, 235, 241
  probes, 9, 45, 235
  restriction enzyme analysis, 125, 207
  synthesis, by *L. pneumophila*, 37
Dot blotting
  antiserum against *H. ducreyi*, 219
  typing of *N. meningitidis*, 195

Electronmicroscopy
  L. pneumophila, response to antibiotics, 37
  P. pseudomallei in phagocytes, 109
  scanning, 37
  transmission, 109
ELISA
  detection of *C. difficile* toxin B, 251
  typing of *N. meningitidis*, 195
Endotoxin, bacterial, 73
  biological effects, 76
  clinical associations, 75
  implications for treatment, 79
  measurement, 78
  sources, 77
  structure and chemical nature, 73
Enterotoxins, of *E. coli*, 185
Enzyme immunoassay
  antibody response to *Salmonella* vaccine, 225
Epidemiology
  methicillin-resistant *S. aureus*, 125
  trimethoprim resistance, 1, 14

Erythromycin, and *L. pneumophila*, 37
Escherichia coli
in bacteraemia, 175
cytotoxic necrotising factor, 175
DNA degradation by 4-quinolones, 65
enteropathogenic (EPEC), 235
enterotoxigenic (ETEC), 185
EPEC adherence factor, 235
P fimbriae, 175
plasmids, 213, 241
resistance to 4-quinolones, 154
toxin polymorphism, 241
trimethoprim resistance, 213
Vero cytotoxin genes, 235
Eubacterium yurii
pathogenic potential, 103
role in periodontal disease, 103
Exonuclease V, 65

Faeces
detection of *C. difficile* toxin B, 251
E. coli in, 175, 235
Fatty acid markers, 21
Fibronectin binding, by *S. milleri* group, 259
Fimbriae, of *E. coli*, 175
Flow cytometric analysis, 191
Fluid secretion
S. typhimurium, in ileal loop, 27
Fusobacterium spp.
in broken mouth periodontitis, 275

Gas chromatography, 275
with mass spectrometry, 21
Gene cloning, 213

Haemagglutination tests, 175
Haemolysin, of *E. coli*, 175
Haemophilus
H. ducreyi, immunodiagnostic tests, 219
H. ducreyi, monoclonal antibodies, 219
H. influenzae, outer membrane proteins, 163
Hamster model
hydrolytic enzymes of *C. difficile*, 169
Hybridisation of DNA
conjugative plasmid of *S. aureus*, 207
dihydrofolate reductase gene, 213
EPEC adherence factor, 235
toxin polymorphism of *E. coli*, 241
trimethoprim resistance studies, 9
typing method for *L. pneumophila*, 45
Vero cytotoxin gene, 235
Hydrolytic enzyme activity
of *C. difficile*, 169
Hydrophobicity
of *E. coli*, 175
of *S. milleri* group, 259

Ileal loops
fluid secretion, and *S. typhimurium*, 27
Immunisation
chick embryos against *S. minnesota*, 85
mice against poliomyelitis, 115
mice against *S. choleraesuis*, 225
mice against *S. typhimurium*, 95, 225
mice against yellow fever, 115
Immunoblotting
antibodies against *H. influenzae*, 163
characterisation of *S. aureus*, 125
monoclonal antibodies against *H. ducreyi*, 219
typing of *N. meningitidis* strains, 195
Immunofluorescence assays
host response to *S. typhimurium*, 191
immunodiagnosis of *H. ducreyi*, 219
Incompatibility testing, 207
Indomethacin, anti-secretory effects, 27
Irradiation techniques, and neutropenia, 27
Iso-electric focusing, 213

Legionella pneumophila
responses to antibiotics, 37
restriction fragment length polymorphisms, 45
typing method, 45
ultrastructural studies, 37
Leucocyte
influx, in ileal loops, 27
interactions with *P. pseudomallei*, 109
Limulus amoebocyte-lysate assay, 78
Lipid A, 73, 85
Lipopolysaccharide, LPS
endotoxin and endotoxaemia, 73
of salmonellae, and antibody response, 225
of *S. minnesota*, 85
of *S. typhimurium*, 95
structure and chemical nature, 73
Listeria monocytogenes
pyrolysis-mass spectrometry, 137
Lymphocyte response, to *S. typhimurium*, 191

Mannose sensitivity, of *E. coli*, 175
Mass spectrometry
and gas chromatography, 21
pyrolysis-mass spectrometry, 137
Melioidosis, 109
Meningitis, bacterial
rapid diagnosis, 21
Meningococci *see Neisseria meningitidis*
Methicillin
resistance of *S. aureus*, 4, 11, 57, 125
sensitivity of *L. pneumophila*, 37
Monoclonal antibodies
against *H. ducreyi*, 219
against *N. meningitidis*, 195
against *S. minnesota*, 85
Mouse model
cytogenetic effects of viral vaccines, 11
enterotoxigenic *E. coli* infection, 185
host response to *S. typhimurium*, 191
immunisation against *S. typhimurium*, 95

Mycoplasma spp.
viability after long-term storage, 203

Nalidixic acid
DNA degradation in *E. coli*, 65
mechanisms of resistance, 153
Neisseria meningitidis
monoclonal antibodies, 195
rapid diagnosis of meningitis, 21
serotyping and subtyping, 195
Neutropenia, induction techniques, 27
Nitrogen mustard treatment, 27
Norfloxacin
DNA degradation in *E. coli*, 65

Outer membrane protein, of *H. influenzae*, 163

Periodontal disease
anaerobic flora in broken mouth of sheep, 275
role of *E. yurii*, 103
Phage typing, *P. aeruginosa*, 119
Phagocytosis
P. pseudomallei by leucocytes, 109
Plasmids
conjugative, of *S. aureus*, 207
methicillin resistance of *S. aureus*, 57
4-quinolone resistance, 153
restriction enzyme analysis of *S. aureus*, 125
toxin polymorphism of *E. coli*, 241
trimethoprim resistance, 1, 213
typing method for *L. pneumophila*, 45
typing method for *S. aureus*, 57
Poliomyelitis vaccine, 115
Polymorphonuclear leucocytes, PMNL
interactions with *P. pseudomallei*, 109
PROCEEDINGS OF THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND Vol. 31 No. 4 April 1990 pp i–ixx
Protein
outer membrane of *H. influenzae*, 163
synthesis, by *L. pneumophila*, 37
Pseudomonas
P. aeruginosa, in cystic fibrosis, 119
P. aeruginosa, resistance to 4-quinolones, 156
P. pseudomallei, survival in phagocytes, 109
Pyocin typing, 119
Pyrolysis-mass spectrometry, 137

4-Quinolones
DNA degradation in *E. coli*, 65
mechanisms of resistance, 153

Radiolabelling, 65
Restriction enzyme analysis
characterisation of *S. aureus*, 125
conjugative plasmid of *S. aureus*, 207
Restriction fragment length polymorphisms, 4
Rifampicin, and *L. pneumophila*, 37

Salmonellae
S. choleraesuis, vaccine, 225
S. minnesota, monoclonal antibodies, 85
S. minnesota, pathophysiological effects, 85
S. typhimurium, fluid secretion in ileal loops, 27
S. typhimurium, host response in mouse model, 191
S. typhimurium, immunisation of mice, 95
S. typhimurium, lipopolysaccharide, 95
S. typhimurium, role of leucocytes in infection, 27
S. typhimurium, vaccine, 225
SDS-PAGE
epidemiological analysis of *S. aureus*, 125
outer membrane proteins of *H. influenzae*, 163
typing of *N. meningitidis*, 195
Selected ion monitoring, 21
Septic shock, 75, 79
Serogrouping, of *E. coli*, 175
Serotyping
N. meningitidis, 195
P. aeruginosa, 119
Southern blotting, 45
Sputum
of cystic fibrosis patients, 119, 271
H. influenzae isolates, 163
P. aeruginosa isolates, 119
Staphylococci
plasmids, 4, 11
S. aureus, antibiotic sensitivity, 57
S. aureus, characterisation, 125
S. aureus, clinical importance, 11
S. aureus, epidemiology, 125
S. aureus, methicillin resistance, 4, 11, 57, 125
S. aureus plasmids, 4, 57, 125, 207
S. aureus, trimethoprim resistance, 4, 11
S. aureus, typing method, 57
S. epidermidis, clinical importance, 4, 11
S. epidermidis, trimethoprim resistance, 4, 11
trimethoprim resistance, 4, 11
Streptococci
S. milleri (anginosus) group, pathogenicity, 259
S. milleri (anginosus) group, surface-associated properties, 259
S. pneumoniae, chloramphenicol resistance, 133

Toxins
of *E. coli*, 175, 241
polymorphism, 241
toxin B of *C. difficile*, 251
see also Endotoxin
Trimethoprim resistance
epidemiology, 1, 14
in gram-negative bacteria, 1, 7, 213
in staphylococci, 4, 11
Tumour necrosis factor, 77

Ureaplasmas
viability after long-term storage, 203

Vaccines
  against poliomyelitis, 115
  against *S. choleraesuis*, 225
  against *S. typhimurium*, 95, 225
  against yellow fever, 115
  viral, cytogenetic effects, 115
Vero cytotoxin, 235
Viral vaccines, 115
Virulence factors
  C. difficile, 169
  E. coli, 175, 185
  E. yurii, 103
  S. milleri group, 225
  S. typhimurium, 27

Yellow fever vaccine, 115

INDEX OF AUTHORS FOR VOLUME 31

ACAR J F, *see* GOLDSTEIN AND ACAR, 1
AITCHISON G U, *see* MCCOURTIE *et al.*, 275
ALLEN RUTH A, *see* LEWIN *et al.*, 153
ALONSO M P, *see* BLANCO *et al.*, 175
AMYES S G B, TAIT S. Trimethoprim resistance in staphylococci, 4
AMYES S G B, TOWNER K J. Trimethoprim resistance; epidemiology and molecular aspects, 1
AMYES S G B, *see* LEWIN *et al.*, 153
AMYES S G B, *see* THOMSON *et al.*, 213
ASWAPOKEE NALINEE, *see* PRUKSACHARTVUTHI *et al.*, 109

BAIRD D, *see* COIA *et al.*, 125
BAYSTON KATHERINE F, COHEN J. Bacterial endotoxin and current concepts in the diagnosis and treatment of endotoxaemia, 73
BERTIN ANNE, *see* DUCHET-SUCHAUX *et al.*, 185
BISSERET F, *see* NGUYEN *et al.*, 251
BLANCO J, ALONSO M P, GONZALEZ E A, BLANCO M, GARABAL J I. Virulence factors of bacteraemic *Escherichia coli* with particular reference to production of cytotoxic necrotising factor (CNF) by P-fimbriate strains, 175
BLANCO M, *see* BLANCO J *et al.*, 175
BORRIELLO S P, *see* SEDDON *et al.*, 169
BORST J, *see* HORREVORTS *et al.*, 119
BROWN D F J, *see* WALKER AND BROWN, 133
BROWN M R W, *see* MACIVER *et al.*, 163
BROWN R, *see* MCCOURTIE *et al.*, 275
BURDESKA A, THEN R L. Clinical importance of trimethoprim resistance in staphylococci isolated in Europe, 11

CANDY D C A, *see* WALLIS *et al.*, 27
CHAN C Y, *see* FRENCH *et al.*, 21
CHENG A F B, *see* FRENCH *et al.*, 21
CHEUNG S W, *see* FRENCH *et al.*, 21
CLARKE C J, *see* WALLIS *et al.*, 27
COHEN J, *see* BAYSTON AND COHEN, 73
COIA J E, THOMSON-CARTER FIONA, BAIRD D, PLATT D J. Characterisation of methicillin-resistant *Staphylococcus aureus* by biotyping, immunoblotting and restriction enzyme fragmentation patterns, 125

DEGENER J E, *see* HORREVORTS *et al.*, 119
DING H F, NAKONECZNA IRENE, HSU H S. Protective immunity induced in mice by detoxified salmonella lipopolysaccharide, 95
DUCHET-SUCHAUX MARION, LE MAITRE CAROLE, BERTIN ANNE. Differences in susceptibility of inbred and outbred infant mice to enterotoxigenic *Escherichia coli* of bovine, porcine and human origin, 185
DUERDEN B I, *see* HINDMARCH *et al.*, 137
DZOLJIC-DANILOV G, *see* HORREVORTS *et al.*, 119

EASMON C S F, *see* FINN *et al.*, 219
EASMON C S F, *see* MEHTA *et al.*, 85
ELLIOTT T S J, *see* RODGERS *et al.*, 37

FINN GEETA Y, KARIM NAJMA Q, EASMON C S F. The production and characterisation of rabbit antiserum and murine monoclonal antibodies to *Haemophilus ducreyi*, 219
FRENCH G L, CHAN C Y, POON D, CHEUNG S W, CHENG A F B. Rapid diagnosis of bacterial meningitis by the detection of a fatty acid marker in CSF with gas chromatography-mass spectrometry and selected ion monitoring, 21
FRØHOLM L O, *see* WEDEGE *et al.*, 195
FURR PATRICIA M, TAYLOR-ROBINSON D. Long-term viability of stored mycoplasmas and ureaplasmas, 203

GARABAL J I, *see* BLANCO *et al.*, 175
GILLESPIE M T, LYON B R, SKURRAY R A. Typing of methicillin-resistant *Staphylococcus aureus* by antibiotic resistance phenotypes, 57
GIRARDOT R, *see* NGUYEN *et al.*, 251
GOLDSTEIN F W, ACAR J F. Evolution and spread of trimethoprim resistance in gram-negative bacteria, 1
GONZALEZ E A, *see* BLANCO *et al.*, 175
GRUBB W B, *see* UDO AND GRUBB, 207

HADFIELD M A, *see* HINDMARCH *et al.*, 137
HARRISON T G, *see* SAUNDERS *et al.*, 45
HATHTHOTUWA ARUNI, *see* SAUNDERS *et al.*, 45
HEATH J R, *see* MARGARET *et al.*, 103
HECKEL C, *see* NGUYEN *et al.*, 251
HEMINGWAY I, *see* SEDDON *et al.*, 169
HINDMARCH J M, MAGEE J T, HADFIELD M A, DUERDEN B I. A pyrolysis-mass spectrometry study of *Corynebacterium* spp., 137
HØIBY E A, *see* WEDEGE *et al.*, 195
HORREVORTS A M, BORST J, PUYK R J T, RIDDER R DE, DZOLJIC-DANILOVIC G, DEGENER J E, KERREBIJN K F, MICHEL M F. Ecology of *Pseudomonas aeruginosa* in patients with cystic fibrosis, 119
HSU H S, *see* DING *et al.*, 95

JEWES LINDA A, SPENCER R C. The incidence of anaerobes in the sputum of patients with cystic fibrosis, 271

KACHWALLA NAFISA, *see* SAUNDERS *et al.*, 45
KARIM NAJMA Q, *see* FINN *et al.*, 219
KERREBIJN K F, *see* HORREVORTS *et al.*, 119
KNOX K W, *see* WILLCOX AND KNOX, 259
KRYWOLAP G N, *see* MARGARET *et al.*, 103

LE MAITRE CAROLE, *see* DUCHET-SUCHAUX *et al.*, 185

LEWIN C S, ALLEN RUTH A, AMYES S G B. Potential mechanisms of resistance to the modern fluorinated 4-quinolones, 153
LEWIN C S, SMITH J T. DNA breakdown by the 4-quinolones and its significance, 65
LYON B R, *see* GILLESPIE *et al.*, 57

MCCOURTIE J, POXTON I R, BROWN R, WHITTAKER C R, SPENCE J A, AITCHISON G U. A longitudinal study of the cultivable subgingival anaerobic bacteria isolated from sheep during the development of broken mouth periodontitis, 275
MACIVER I, O'REILLY T, BROWN M R W. Porphyrin ring source can alter the outer membrane protein profile of non-typable *Haemophilus influenzae*, 163
MAGEE J T, *see* HINDMARCH *et al.*, 137
MARGARET BARBARA S, HEATH J R, KRYWOLAP G N. Pathogenic potential of *Eubacterium yurii* subspecies, 103
MEE B J. The dissemination of trimethoprim resistance plasmids in a large isolated community, 14
MEHTA N D, WILSON B M, RAPSON N T, EASMON C S F. A comparison of specificity and biological activity of polyclonal and monoclonal antibodies raised against *Salmonella minnesota* R595 lipopolysaccharide, 85
MICHEL M F, *see* HORREVORTS *et al.*, 119
MONTEIL H, *see* NGUYEN *et al.*, 251

NAKONECZNA IRENE, *see* DING *et al.*, 95
NGUYEN V K, RIHN B, HECKEL C, BISSERET F, GIRARDOT R, MONTEIL H. Enzyme immunoassay (ELISA) for detection of *Clostridium difficile* toxin B in specimens of faeces, 251
NNALUE N A. Mice vaccinated with a non-virulent aromatic-dependent mutant of *Salmonella choleraesuis* die from challenge with its virulent parent but survive challenge with *Salmonella typhimurium*, 225

O'REILLY T, *see* MACIVER *et al.*, 163
OSBORNE M P, *see* WALLIS *et al.*, 27

PLATT D J, *see* COIA *et al.*, 125
POLASA H, *see* RAO AND POLASA, 115
POON D, *see* FRENCH *et al.*, 21
POXTON I R, *see* MCCOURTIE *et al.*, 275
PRUKSACHARTVUTHI SURAPEE, ASWAPOKEE NALINEE, THANKERNGPOL KLEOPHANT. Survival of *Pseudomonas pseudomallei* in human phagocytes, 109
PUYK R J T, *see* HORREVORTS *et al.*, 119

QI G-M, *see* WALLIS *et al.*, 27

RAO L V, POLASA H. Chromosomal aberrations in germ cells of male mice immunised with attenuated viral vaccines (human), 115
RAPSON N T, *see* MEHTA *et al.*, 85
RIDDER R DE, *see* HORREVORTS *et al.*, 119
RIDHA G A, *see* WOODWARD *et al.*, 241
RIHN B, *see* NGUYEN *et al.*, 251
RODGERS F G, TZIANABOS A O, ELLIOTT T S J. The effect of antibiotics that inhibit cell-wall, protein and DNA synthesis on the growth and morphology of *Legionella pneumophila*, 37
ROSENQVIST E, *see* WEDEGE *et al.*, 195
ROWE B, *see* SMITH *et al.*, 235

SAUNDERS N A, HARRISON T G, HATHTHOTUWA ARUNI, KACHWALLA NAFISA, TAYLOR A G. A method for typing strains of *Legionella pneumophila* serogroup 1 by analysis of restriction fragment length polymorphisms, 45
SCOTLAND S M, *see* SMITH *et al.*, 235
SEDDON S V, HEMINGWAY I, BORRIELLO S P. Hydrolytic enzyme production by *Clostridium difficile* and its relationship to toxin production and virulence in the hamster model, 169
SETO A, *see* TAKAHASHI *et al.*, 191
SKURRAY R A, *see* GILLESPIE *et al.*, 57
SMITH H R, SCOTLAND S M, STOKES N, ROWE B. Examination of strains belonging to enteropathogenic *Escherichia coli* serogroups for genes encoding EPEC adherence factor and Vero cytotoxins, 235
SMITH J T, *see* LEWIN AND SMITH, 65
SPENCE J A, *see* MCCOURTIE *et al.*, 275
SPENCER R C, *see* JEWES AND SPENCER, 271
STEPHEN J, *see* WALLIS *et al.*, 27
STOKES N, *see* SMITH *et al.*, 235

TAIT S, *see* AMYES AND TAIT, 4
TAKAHASHI M, USHIJIMA T, SETO A. Comparison of host responses induced by *Salmonella typhimurium* infection in genetically resistant and susceptible mice, 191
TAYLOR A G, *see* SAUNDERS *et al.*, 45
TAYLOR-ROBINSON D, *see* FURR AND TAYLOR-ROBINSON, 203
THANKERNGPOL KLEOPHANT, *see* PRUKSACHARTVUTHI *et al.*, 109
THEN R L, *see* BURDESKA AND THEN, 11
THOMSON C J, TOWNER K J, YOUNG H-K, AMYES S G B. Identification and cloning of the Type IIIa plasmid-encoded dihydrofolate reductase gene from trimethoprim-resistant gram-negative bacteria isolated in Britain, 213
THOMSON C J, *see* YOUNG AND THOMSON, 7
THOMSON-CARTER FIONA, *see* COIA *et al.*, 125
TOWNER K J. DNA probes for trimethoprim-resistant dihydrofolate reductases, 9
TOWNER K J, *see* AMYES AND TOWNER, 1
TOWNER K J, *see* THOMSON *et al.*, 213
TZIANABOS A O, *see* RODGERS *et al.*, 37

UDO E E, GRUBB W B. A new class of conjugative plasmid in *Staphylococcus aureus*, 207
USHIJIMA T, *see* TAKAHASHI *et al.*, 191

VAUGHAN A T M, *see* WALLIS *et al.*, 27

WALKER C W, BROWN D F J. A rapid technique for detection of resistance to chloramphenicol in *Streptococcus pneumoniae* and comparison with minimum inhibitory concentration and disk-diffusion methods, 133

WALLIS T S, VAUGHAN A T M, CLARKE G J, QI G-M, WORTON K J, CANDY D C A, OSBORNE M P, STEPHEN J. The role of leucocytes in the induction of fluid secretion by *Salmonella typhimurium*, 27

WALTON J R, *see* WOODWARD *et al.*, 241

WEDEGE E, HØIBY E A, ROSENQVIST E, FRØHOLM L O. Serotyping and subtyping of *Neisseria meningitidis* isolates by co-agglutination, dot-blotting and ELISA, 195

WHITTAKER C R, *see* MCCOURTIE *et al.*, 275

WILLCOX M D P, KNOX K W. Surface-associated properties of *Streptococcus milleri* group strains and their potential relation to pathogenesis, 259

WILSON B M, *see* MEHTA *et al.*, 85

WOODWARD M J, WRAY C, RIDHA G A, WALTON J R. Plasmid and chromosomal related toxin polymorphism of *Escherichia coli* serogroup O138; plasmid transfer and co-integration with pRP4, 241

WORTON K J, *see* WALLIS *et al.*, 27

WRAY C, *see* WOODWARD *et al.*, 241

YOUNG H-K, THOMSON C J. Plasmid-encoded trimethoprim-resistant dihydrofolate reductases in gram-negative bacteria, 7

YOUNG H-K, *see* THOMSON *et al.*, 213